top of page
  • Facebook
  • Twitter
  • Instagram

Reshaping patients' life with the cutting-edge treatment 

A​bout Ariella

We are a UK-based pharmaceutical company aiming to deliver transformative therapy for people battling with neurodegenerative disorders.  

Exterior of a Building
Science Lab

Our therapeutics

Our nucleic acid therapy, Nominsen®, that directly targets the mutant gene of Huntington's disease, is expected to obtain FDA and MHRA approval in January 2024 and is planned to be commercially available in June 2024.

We are working as a team

We are proud of our excellent team, which is comprised of experts in R&D, marketing, operations, and business, as well as our contributions to creating a supportive and inclusive environment at Ariella.

If you are interested in being a force to develop nucleic acid therapy for transforming patients' lives, come join our team.

Business Team

© 2024 Ariella Pharmaceuticals

 

Disclaimer: Ariella Pharmaceuticals is a fictional company and Nominsen is a fictitious product. They were both created for University College London's BIOC0015 coursework. Any similarity to real businesses, individuals, or other technologies is coincidental. 

bottom of page